SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces it will be hosting an information session dedicated to its planned STAR pivotal trial and scleroderma, featuring principal investigator Dr. Dinesh Khanna. The session will be held on January 14, 2015, from 1:30 PM to 4:30 PM at the Prescott Hotel, 545 Post Street, San Francisco, Room 736.
The STAR pivotal trial is expected to commence in 2015 and will evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 people in the United States.
The January 14th informational session will provide an opportunity to understand the epidemiology of scleroderma and the planned trial design, to review previous trial data and other scientific support, and to learn about the scleroderma market opportunity.
About Dr. Dinesh Khanna
Dinesh Khanna, MD, MS, the Frederick G.L. Huetwell Professor of Rheumatology and an Associate Professor of Internal Medicine, is the director of the University of Michigan Scleroderma Program. He has also served as Clinical Director of UCLA’s Scleroderma Clinic.
Dr. Khanna is the author of over 160 peer-reviewed publications and book chapters. He has won numerous awards, including the 2007 Spirit of Leadership Award and the 2011 “Best Doctor of the Year” award from the Scleroderma Foundation. He is board certified in rheumatology. Dr. Khanna is currently funded by the National Institutes of Health and is particularly interested in the design of clinical trials and assessing patient reported outcomes in patients with scleroderma and leading novel international clinical trials in scleroderma.
Dr. Khanna is a fellow of the American College of Rheumatology. He was elected by his peers to the 2011-2012 Best Doctors in America, which recognizes the area’s top clinicians.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary solutions. For more information: visit www.cytori.com or follow Cytori on Twitter www.twitter.com/cytori.